Compare BioNTech SE - ADR (BNTX) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Oracle Corporation — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Oracle Corporation trades at $129.27 (market cap $368.53B). The key difference: Oracle Corporation is far larger — about 16.1× BioNTech SE - ADR's market cap, and Oracle Corporation pays a 1.56% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | ORCL | |
|---|---|---|
Market Cap | $22.86B | $368.53B |
Sector | Health | Technology |
52-Week High | $119.34 | $328.33 |
52-Week Low | $83.89 | $127.96 |
Enterprise Value | $6.53B | $497.78B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Oracle Corporation (ORCL) is trading at $127.96, down 9.04% today, reflecting recent market volatility. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $2.11 vs. $1.96 expected) and robust profitability (net margin of 25.37%). Technical indicators are bearish with support at $124, while analyst consensus remains bullish with a $259 price target. Recent news highlights Oracle's AI infrastructure expansion and partnership with OpenAI.
Outlook: Oracle's AI-driven growth and solid financials support long-term upside, but near-term risks include high debt levels and competitive pressures. The stock offers value for investors seeking exposure to enterprise software and cloud infrastructure, with earnings on June 10, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
